••
The Federal Government of Nigeria’s pilot program for the HIV-prevention drug Lenacapavir is facing significant challenges as supplies have been depleted across several states. The shortage follows an unexpected surge in demand for the twice-yearly injectable, which has become highly sought after by sex workers and other eligible citizens. Reports indicate that stock-outs are particularly severe in Benue, Kwara, Gombe, and Cross River, occurring shortly after the medication was first made available under the government’s new health initiative. This rapid depletion highlights both the success of the initial outreach and the current strain on the medical supply chain. Lenacapavir represents a significant advancement in HIV prevention, offering a long-acting alternative to daily oral pre-exposure prophylaxis (PrEP). The preference for a twice-yearly injection is driven by its convenience and the reduced burden of daily pill-taking, which is often a barrier for those at high risk of infection. However, the scramble for the jab in the pilot states suggests that the initial allocation of doses was insufficient to meet the public's appetite for this modern preventive measure. Health officials in the affected regions are now grappling with how to manage expectations and secure additional supplies. The current situation in states like Gombe and Cross River underscores the necessity of robust logistics in the rollout of new medical technologies. While the pilot program was intended to test the feasibility of the drug's use in Nigeria, the immediate stock-out provides a clear signal that a much larger scale of distribution will be required to effectively serve the target populations. Moving forward, the Federal Government and health stakeholders must address these supply gaps to maintain momentum in the fight against HIV. The success of future prevention strategies will depend on ensuring that breakthrough treatments like Lenacapavir are not only available in theory but are consistently accessible to the Nigerians who need them most. The lessons learned from this initial 'scramble' will be vital for the eventual nationwide integration of long-acting injectables into the national health framework.